A Retrospective Case Series of Telavancin for the Treatment of Staphylococcus aureus Bacteremia: A Real-World Experience

Louis D. Saravolatz, Kerry Cleveland, Khalid Rikabi, Ali Hassoun, Joseph Reilly, Leonard B. Johnson, Cedric Spak, Sharon Valenti, Susan Szpunar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose Telavancin (TLV) is approved for complicated skin and skin structure infections and hospital-acquired pneumonia. This report represents a retrospective analysis of patients with Staphylococcus aureus bacteremia who, at the physician's discretion, received TLV at some time during their course. Methods The primary outcome measure was the percent of patients cured or improved at the end of TLV therapy (EOTT). The secondary outcome was the percent of patients cured or improved at least 30 days after discontinuation of TLV therapy. Results There were 46 cases of S. aureus bacteremia, with 44 (95.7%) being methicillin-resistant S. aureus and 2 (4.3%) methicillin-susceptible S. aureus. At EOTT, 30 (65.2%) were considered cured, 9 (19.6%) had an incomplete response, and 7 (15.2%) had died. At the 30-day follow-up after EOTT, 32 were cured (69.6%), 6 (13%) had an incomplete response, and 8 (17.4%) had died. For the 7 patients who died by EOTT, 2 deaths were not associated with infection. While there was no difference in the median length of stay between patients who were cured, had incomplete response, or died, the median duration of TLV therapy for the cured group was 29.5 days (minimum, 4; 25th percentile, 14.75; 75th percentile, 42.0; maximum, 67 days) compared with 11 days (minimum, 1; 25th percentile, 5; 75th percentile, 34; maximum, 47 days) for those with an incomplete response and 4 days (minimum, 1; 25th percentile, 1; 75th percentile, 15; maximum, 15 days) for those who died. Additional antibiotics were permitted prior to, concurrent with, and after TLV. More than 78% of patients received antibiotics prior to TLV (n = 36), 30.4% received antibiotics concurrent with TLV (n = 14), and 19.6% received antibiotics after TLV (n = 9). Five patients received TLV only. The median duration of antibiotics prior to TLV was 4 days (minimum, 1; 25th percentile, 2; 75th percentile, 7.75; maximum, 25 days). The median duration of antibiotics concurrent with TLV was 5 days (minimum, 1; 25th percentile, 1; 75th percentile, 11; maximum, 37 days). The median duration of antibiotics after TLV was 19 days (minimum, 2; 25th percentile, 10.5; 75th percentile, 117.5; maximum, 545 days). When comparing patients who were cured versus those who had an incomplete response, 26 (89.7%) of 29 patients who received TLV longer than any other antibiotic before EOTT were cured compared with 4 (40.0%) of 10 patients who received TLV for a shorter number of days than other antibiotics (P = 0.001). The most common adverse effect was anemia in 9 (19.6%), followed by rises in hepatic enzymes and serum creatinine in 5 (10.9%) each. No adverse events led to the discontinuation of TLV therapy. Conclusions Although it is difficult to determine the efficacy of TLV by itself, patients who received TLV for a longer duration than other antibiotics before EOTT were more likely to be cured as opposed to having an incomplete response compared with patients who received TLV as a smaller proportion of their total antibiotic days. A favorable outcome was achieved for many patients receiving the antimicrobial regimen that included TLV for the treatment of methicillin-resistant S. aureus bacteremia.

Original languageEnglish (US)
Pages (from-to)264-269
Number of pages6
JournalInfectious Diseases in Clinical Practice
Volume26
Issue number5
DOIs
StatePublished - Sep 1 2018

Fingerprint

Bacteremia
Staphylococcus aureus
Anti-Bacterial Agents
Therapeutics
telavancin
Methicillin-Resistant Staphylococcus aureus
Skin
Methicillin
Group Psychotherapy
Cross Infection

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

A Retrospective Case Series of Telavancin for the Treatment of Staphylococcus aureus Bacteremia : A Real-World Experience. / Saravolatz, Louis D.; Cleveland, Kerry; Rikabi, Khalid; Hassoun, Ali; Reilly, Joseph; Johnson, Leonard B.; Spak, Cedric; Valenti, Sharon; Szpunar, Susan.

In: Infectious Diseases in Clinical Practice, Vol. 26, No. 5, 01.09.2018, p. 264-269.

Research output: Contribution to journalArticle

Saravolatz, Louis D. ; Cleveland, Kerry ; Rikabi, Khalid ; Hassoun, Ali ; Reilly, Joseph ; Johnson, Leonard B. ; Spak, Cedric ; Valenti, Sharon ; Szpunar, Susan. / A Retrospective Case Series of Telavancin for the Treatment of Staphylococcus aureus Bacteremia : A Real-World Experience. In: Infectious Diseases in Clinical Practice. 2018 ; Vol. 26, No. 5. pp. 264-269.
@article{6693b42cc9ab4004857803340e4246cf,
title = "A Retrospective Case Series of Telavancin for the Treatment of Staphylococcus aureus Bacteremia: A Real-World Experience",
abstract = "Purpose Telavancin (TLV) is approved for complicated skin and skin structure infections and hospital-acquired pneumonia. This report represents a retrospective analysis of patients with Staphylococcus aureus bacteremia who, at the physician's discretion, received TLV at some time during their course. Methods The primary outcome measure was the percent of patients cured or improved at the end of TLV therapy (EOTT). The secondary outcome was the percent of patients cured or improved at least 30 days after discontinuation of TLV therapy. Results There were 46 cases of S. aureus bacteremia, with 44 (95.7{\%}) being methicillin-resistant S. aureus and 2 (4.3{\%}) methicillin-susceptible S. aureus. At EOTT, 30 (65.2{\%}) were considered cured, 9 (19.6{\%}) had an incomplete response, and 7 (15.2{\%}) had died. At the 30-day follow-up after EOTT, 32 were cured (69.6{\%}), 6 (13{\%}) had an incomplete response, and 8 (17.4{\%}) had died. For the 7 patients who died by EOTT, 2 deaths were not associated with infection. While there was no difference in the median length of stay between patients who were cured, had incomplete response, or died, the median duration of TLV therapy for the cured group was 29.5 days (minimum, 4; 25th percentile, 14.75; 75th percentile, 42.0; maximum, 67 days) compared with 11 days (minimum, 1; 25th percentile, 5; 75th percentile, 34; maximum, 47 days) for those with an incomplete response and 4 days (minimum, 1; 25th percentile, 1; 75th percentile, 15; maximum, 15 days) for those who died. Additional antibiotics were permitted prior to, concurrent with, and after TLV. More than 78{\%} of patients received antibiotics prior to TLV (n = 36), 30.4{\%} received antibiotics concurrent with TLV (n = 14), and 19.6{\%} received antibiotics after TLV (n = 9). Five patients received TLV only. The median duration of antibiotics prior to TLV was 4 days (minimum, 1; 25th percentile, 2; 75th percentile, 7.75; maximum, 25 days). The median duration of antibiotics concurrent with TLV was 5 days (minimum, 1; 25th percentile, 1; 75th percentile, 11; maximum, 37 days). The median duration of antibiotics after TLV was 19 days (minimum, 2; 25th percentile, 10.5; 75th percentile, 117.5; maximum, 545 days). When comparing patients who were cured versus those who had an incomplete response, 26 (89.7{\%}) of 29 patients who received TLV longer than any other antibiotic before EOTT were cured compared with 4 (40.0{\%}) of 10 patients who received TLV for a shorter number of days than other antibiotics (P = 0.001). The most common adverse effect was anemia in 9 (19.6{\%}), followed by rises in hepatic enzymes and serum creatinine in 5 (10.9{\%}) each. No adverse events led to the discontinuation of TLV therapy. Conclusions Although it is difficult to determine the efficacy of TLV by itself, patients who received TLV for a longer duration than other antibiotics before EOTT were more likely to be cured as opposed to having an incomplete response compared with patients who received TLV as a smaller proportion of their total antibiotic days. A favorable outcome was achieved for many patients receiving the antimicrobial regimen that included TLV for the treatment of methicillin-resistant S. aureus bacteremia.",
author = "Saravolatz, {Louis D.} and Kerry Cleveland and Khalid Rikabi and Ali Hassoun and Joseph Reilly and Johnson, {Leonard B.} and Cedric Spak and Sharon Valenti and Susan Szpunar",
year = "2018",
month = "9",
day = "1",
doi = "10.1097/IPC.0000000000000652",
language = "English (US)",
volume = "26",
pages = "264--269",
journal = "Infectious Diseases in Clinical Practice",
issn = "1056-9103",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A Retrospective Case Series of Telavancin for the Treatment of Staphylococcus aureus Bacteremia

T2 - A Real-World Experience

AU - Saravolatz, Louis D.

AU - Cleveland, Kerry

AU - Rikabi, Khalid

AU - Hassoun, Ali

AU - Reilly, Joseph

AU - Johnson, Leonard B.

AU - Spak, Cedric

AU - Valenti, Sharon

AU - Szpunar, Susan

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Purpose Telavancin (TLV) is approved for complicated skin and skin structure infections and hospital-acquired pneumonia. This report represents a retrospective analysis of patients with Staphylococcus aureus bacteremia who, at the physician's discretion, received TLV at some time during their course. Methods The primary outcome measure was the percent of patients cured or improved at the end of TLV therapy (EOTT). The secondary outcome was the percent of patients cured or improved at least 30 days after discontinuation of TLV therapy. Results There were 46 cases of S. aureus bacteremia, with 44 (95.7%) being methicillin-resistant S. aureus and 2 (4.3%) methicillin-susceptible S. aureus. At EOTT, 30 (65.2%) were considered cured, 9 (19.6%) had an incomplete response, and 7 (15.2%) had died. At the 30-day follow-up after EOTT, 32 were cured (69.6%), 6 (13%) had an incomplete response, and 8 (17.4%) had died. For the 7 patients who died by EOTT, 2 deaths were not associated with infection. While there was no difference in the median length of stay between patients who were cured, had incomplete response, or died, the median duration of TLV therapy for the cured group was 29.5 days (minimum, 4; 25th percentile, 14.75; 75th percentile, 42.0; maximum, 67 days) compared with 11 days (minimum, 1; 25th percentile, 5; 75th percentile, 34; maximum, 47 days) for those with an incomplete response and 4 days (minimum, 1; 25th percentile, 1; 75th percentile, 15; maximum, 15 days) for those who died. Additional antibiotics were permitted prior to, concurrent with, and after TLV. More than 78% of patients received antibiotics prior to TLV (n = 36), 30.4% received antibiotics concurrent with TLV (n = 14), and 19.6% received antibiotics after TLV (n = 9). Five patients received TLV only. The median duration of antibiotics prior to TLV was 4 days (minimum, 1; 25th percentile, 2; 75th percentile, 7.75; maximum, 25 days). The median duration of antibiotics concurrent with TLV was 5 days (minimum, 1; 25th percentile, 1; 75th percentile, 11; maximum, 37 days). The median duration of antibiotics after TLV was 19 days (minimum, 2; 25th percentile, 10.5; 75th percentile, 117.5; maximum, 545 days). When comparing patients who were cured versus those who had an incomplete response, 26 (89.7%) of 29 patients who received TLV longer than any other antibiotic before EOTT were cured compared with 4 (40.0%) of 10 patients who received TLV for a shorter number of days than other antibiotics (P = 0.001). The most common adverse effect was anemia in 9 (19.6%), followed by rises in hepatic enzymes and serum creatinine in 5 (10.9%) each. No adverse events led to the discontinuation of TLV therapy. Conclusions Although it is difficult to determine the efficacy of TLV by itself, patients who received TLV for a longer duration than other antibiotics before EOTT were more likely to be cured as opposed to having an incomplete response compared with patients who received TLV as a smaller proportion of their total antibiotic days. A favorable outcome was achieved for many patients receiving the antimicrobial regimen that included TLV for the treatment of methicillin-resistant S. aureus bacteremia.

AB - Purpose Telavancin (TLV) is approved for complicated skin and skin structure infections and hospital-acquired pneumonia. This report represents a retrospective analysis of patients with Staphylococcus aureus bacteremia who, at the physician's discretion, received TLV at some time during their course. Methods The primary outcome measure was the percent of patients cured or improved at the end of TLV therapy (EOTT). The secondary outcome was the percent of patients cured or improved at least 30 days after discontinuation of TLV therapy. Results There were 46 cases of S. aureus bacteremia, with 44 (95.7%) being methicillin-resistant S. aureus and 2 (4.3%) methicillin-susceptible S. aureus. At EOTT, 30 (65.2%) were considered cured, 9 (19.6%) had an incomplete response, and 7 (15.2%) had died. At the 30-day follow-up after EOTT, 32 were cured (69.6%), 6 (13%) had an incomplete response, and 8 (17.4%) had died. For the 7 patients who died by EOTT, 2 deaths were not associated with infection. While there was no difference in the median length of stay between patients who were cured, had incomplete response, or died, the median duration of TLV therapy for the cured group was 29.5 days (minimum, 4; 25th percentile, 14.75; 75th percentile, 42.0; maximum, 67 days) compared with 11 days (minimum, 1; 25th percentile, 5; 75th percentile, 34; maximum, 47 days) for those with an incomplete response and 4 days (minimum, 1; 25th percentile, 1; 75th percentile, 15; maximum, 15 days) for those who died. Additional antibiotics were permitted prior to, concurrent with, and after TLV. More than 78% of patients received antibiotics prior to TLV (n = 36), 30.4% received antibiotics concurrent with TLV (n = 14), and 19.6% received antibiotics after TLV (n = 9). Five patients received TLV only. The median duration of antibiotics prior to TLV was 4 days (minimum, 1; 25th percentile, 2; 75th percentile, 7.75; maximum, 25 days). The median duration of antibiotics concurrent with TLV was 5 days (minimum, 1; 25th percentile, 1; 75th percentile, 11; maximum, 37 days). The median duration of antibiotics after TLV was 19 days (minimum, 2; 25th percentile, 10.5; 75th percentile, 117.5; maximum, 545 days). When comparing patients who were cured versus those who had an incomplete response, 26 (89.7%) of 29 patients who received TLV longer than any other antibiotic before EOTT were cured compared with 4 (40.0%) of 10 patients who received TLV for a shorter number of days than other antibiotics (P = 0.001). The most common adverse effect was anemia in 9 (19.6%), followed by rises in hepatic enzymes and serum creatinine in 5 (10.9%) each. No adverse events led to the discontinuation of TLV therapy. Conclusions Although it is difficult to determine the efficacy of TLV by itself, patients who received TLV for a longer duration than other antibiotics before EOTT were more likely to be cured as opposed to having an incomplete response compared with patients who received TLV as a smaller proportion of their total antibiotic days. A favorable outcome was achieved for many patients receiving the antimicrobial regimen that included TLV for the treatment of methicillin-resistant S. aureus bacteremia.

UR - http://www.scopus.com/inward/record.url?scp=85053276098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053276098&partnerID=8YFLogxK

U2 - 10.1097/IPC.0000000000000652

DO - 10.1097/IPC.0000000000000652

M3 - Article

AN - SCOPUS:85053276098

VL - 26

SP - 264

EP - 269

JO - Infectious Diseases in Clinical Practice

JF - Infectious Diseases in Clinical Practice

SN - 1056-9103

IS - 5

ER -